PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

AI in the patent industry: Instant coffee Copilot

  • Technology: Patent law
  • 4th November 2026
It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

Originally posted on IPKat.

It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice. By contrast, every large in-house department is now using AI in some capacity. A large reason for this is Copilot, the “instant coffee” of AI.

Evolve AI

Convenience beats quality

Few people actually like instant coffee or would choose it as their first choice of caffeinated beverage. You drink instant coffee at work because it is easy, quick and it gives you the caffeine you need. Copilot is similar. Copilot arrives bundled with the Microsoft 365 licence. Importantly, from a confidentiality and security perspective, it sits under the same enterprise agreement as everything else the firm already does in Microsoft (you should still check what it is connected to though). It is therefore not surprising that in-house departments, sitting inside large corporates that run on Microsoft, have adopted Copilot wholesale as their AI of first-choice.

We have previously been rather dismissive of Copilot and, at the time, it deserved it. Early Copilot was remarkably poor compared to some of the other frontier LLMs, partly because of the interface Microsoft placed in the way and partly because of the models running underneath. Worse, because Copilot was the only AI tool people had access to at work, its rubbishness gave AI a bad name.

This has changed in recent months. Copilot is now getting better, primarily because the best models from OpenAI and Anthropic are now available as options within it, but also because Microsoft’s own models are improving. Copilot is still a long way from being the best AI tool available, but is now starting to be good enough. We are, incidentally, starting to see a plateau of AI model capabilities. They already have superhuman abilities, and there is a point where most of them are able to do what we need them to do in IP.

AI now works in Microsoft Word

Copilot is part of an important shift in AI over recent months that has kickstarted more widespread adoption in the IP industry. AI has moved out of the browser-based chat window and onto the desktop. The models can now see the context in your folders, open your files and work inside the applications in which you work. You can use them in our old favourites of Word, Excel, PowerPoint and Outlook. Importantly, they have also got better at this and at processing large project folders of context.

For a profession that lives in Word, SharePoint and Outlook, this shift matters a lot. You can now ask an AI to amend a claim set in tracked changes, in the document, without having to launch an entirely different system. There were some amusing predictions six months or so ago that the rise of AI for office work would finally instigate a shift from Word to a better format, such as markdown or LaTeX. Having written a thesis in LaTeX, we had some sympathy with this as an ideal, but no expectation that it would ever happen. Patent attorneys are not moving out of Word and learning a new text editor, no matter how much better this would be. The biggest barrier to most patent attorneys using AI was that they couldn’t use it in Word or in their current folder systems.

Of course, Copilot is not alone in allowing attorneys to work within the familiar and comforting Microsoft environment. All of the big players now have their own desktop-based systems. Anthropic has a desktop application for Claude that can see your folders and work in your files, and Google offers Gemini throughout its enterprise Workspace, with full access to a firm’s Google Drive. However, Copilot remains the leader because it is a simple add-on to the agreements that companies already have with Microsoft (and no-one wants to have to use Google Docs…).

You don’t need to be an expert AI prompt engineer to use AI effectively

Getting started with AI is now also far easier. The models are better at understanding what you want, the tools sit inside the applications you already use, and prompts and instructions can be shared across a team. Of course, the tools remain imperfect, and knowing how to use them properly is still an advantage. However, this is less about being an expert prompt engineer, and instead about knowing what tasks a model is good at, and which it is not, and knowing how to avoid hallucinations and prompt biasing. The difference is that this knowledge is now something every attorney can and should easily pick up. We don’t all need to be expert prompt engineers, we just need some AI experience, and the best way of learning this is just simply to use it.

Of course, there is still the opportunity to take things further and do more with the tools available, should you have access to something beyond Copilot. In the “instant coffee” analogy, in a world of instant coffee, there is always a place for the coffee obsessives, with their own coffee bean grinders, carefully sourced single-origin beans, and obsessive water temperature control. These people make great espressos. But instant coffee will always be more convenient if you want widespread adoption in a large company, and it may be good enough for your purposes.

Expensive coffee pods

So where does this all leave the AI software wrapper companies? We have previously argued that IP firms did not need these companies, on the grounds that attorneys should be upskilling themselves rather than paying for convenience, and that the wrappers added little over the underlying model. This argument has now moved on, because the specialist IP AI wrapper companies are no longer even adding the convenience. Compared to Copilot sitting inside Word, or to the larger legal tech players integrated into a firm’s existing systems, a specialist wrapper is a new system that your attorneys have to learn and an interface you are stuck inside, and integration with your own document systems is harder rather than easier. They are adding nothing, in terms of knowledge, context or capability, that the average attorney cannot now provide for themselves with a skill and a model that lives on their desktop.

Companies that grow up in the gap before a technology fully matures rarely survive. The functionality gap that the AI wrappers filled, namely the interface, the document handling and the prompt engineering, has now largely been closed by Microsoft and the frontier labs. Indeed, each of the big labs now also provides a legal specialist product of its own (Microsoft’s Copilot for Legal being the most recent).

Interestingly, a 2025 MIT survey of enterprise AI adoption, The GenAI Divide, found professionals quietly abandoning the specialist tools their organisations had bought for them. A corporate lawyer at a mid-sized firm whose organisation had invested $50,000 in a specialised contract analysis tool nonetheless defaulted to ChatGPT for her drafting work, explaining that “Our purchased AI tool provided rigid summaries with limited customization options. With ChatGPT, I can guide the conversation and iterate until I get exactly what I need”.

According to the report, the professionals surveyed trusted the generic AI tool more, were already familiar with it, and thought the answers were better. The same lawyer went on to say that “The fundamental quality difference is noticeable, ChatGPT consistently produces better outputs, even though our vendor claims to use the same underlying technology”. The report notably found that general-purpose tools often outperformed bespoke enterprise systems “costing orders of magnitude more”, at least on immediate usability and user satisfaction. This means that even if you spend a lot of time procuring an IP-specialist wrapper tool, you may still be at risk of AI shadow use and low adoption.

In the analogy, the wrapper companies are the coffee pods. They are expensive and not always obvious to use, they lock you into a single specialised machine for which the manufacturer can raise the price of the pods whenever it likes, and they come in lots of different colours that make no difference to what ends up in the cup. You are paying for the pod wrapper, and the simulacrum of convenience and quality. Those people who don’t want the hassle of having to learn to use the pod machine may stick with their instant coffee. People who like good coffee will likely turn their noses up at the coffee quality of the pods and make their own caffeine arrangements.

Analysis

The question is no longer whether patent attorneys will use AI. In-house, they already are, by and large through Copilot. Private practice will follow if they have not already done so, not least because clients who use Copilot every day will expect their attorneys to be at least as efficient. However, Copilot is the instant coffee of the AI world. It is not the best brew, but it has the benefit of being good enough for what is needed and is, most importantly, convenient with low barrier to entry. It is probably also a far more sensible choice for a large company than a coffee pod machine. Meanwhile, however, some people may still think it worth grinding their own coffee beans.

Author: Rose Hughes

Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a patent attorney at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.

With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director, Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialization to SPCs and patent term extensions.

A recognized thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is also a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).

Related insights...

Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: The sneaky practice of prompt injection (and what to do about it)

  • 30th October 2026
As patent attorneys, we are by now all hopefully well versed in the confidentiality and hallucination risks of using AI. However, as AI tools are increasingly used to read, summarise and come to conclusions about third-party documents, there is another risk we need to think about: prompt injection. This is the sneaky practice of hiding…
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information into a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

AI in the patent industry: Bubble trouble and the affordability myth

  • 20th July 2026
Whenever we write about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Podcast: Staring into the AI abyss

  • 14th July 2026
INSIGHT epi – The podcast for European patent professionals
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

AI in the patent industry: The risks of AI shadow use

  • 8th July 2026
In many patent firms, permission to use AI tools is currently restricted to the most senior individuals. Whilst almost every firm seems to have a dedicated “AI task-force” these days to trial new software, this group is usually restricted to partners or senior associates, whilst trainees and more junior associates are denied access to AI…
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert: AI-powered competitive intelligence and IP validity analysis for biotech & pharma

  • 23rd June 2026
Expert analysis based on deep industry expertise, delivered quickly and cost-effectively.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

AI in the patent industry: Don’t believe the hype. Believe the data.

  • 9th June 2026
Many in the IP profession remain considerably sceptical of AI. AI may be useful for checking for typos and simple calculations of deadlines, but it cannot replace in-depth human reasoning about complex scientific and legal issues. However, the data suggests something different.
Turquoise globe on a tilted gold axis with gold bands and a pink equator line on dark blue, Evolve Popper image
Turquoise globe on a tilted gold axis with gold bands and a pink equator line on dark blue, Evolve Popper image

Popper: The global patent prosecution AI for pharmaceutical IP

  • 9th June 2026
Popper is Evolve’s proprietary AI tool, built by our own pharma patent attorneys to navigate the complex intersection of life sciences, global patent law, and commercial strategy.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure